相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene
V. Ziller et al.
CLIMACTERIC (2011)
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims
R. Copher et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Adherence and persistence in patients with severe osteoporosis treated with teriparatide
V. Ziller et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials
M. M. Wilkes et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis
F. -E. Cotte et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Validation of the IOF quality of life questionnaire for patients with wrist fracture
P. Lips et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis
I. Imaz et al.
OSTEOPOROSIS INTERNATIONAL (2010)
TREATMENT OF OSTEOPOROSIS AND PREVENTION OF NEW FRACTURES: ROLE OF INTRAVENOUSLY ADMINISTERED BISPHOSPHONATES
Felicia Cosman
ENDOCRINE PRACTICE (2009)
Quality of life in women with postmenopausal osteoporosis: Correlation between QUALEFFO 41 and SF-36
Neville de Oliveira Ferreira et al.
MATURITAS (2009)
Excess mortality following hip fracture: a systematic epidemiological review
B. Abrahamsen et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women
Julie Blouin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)
Peyman Hadji et al.
JOINT BONE SPINE (2008)
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
S. Boonen et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Bisphosphonates in the management of postmenopausal osteoporosis - optimizing efficacy in clinical practice
Oliver Bock et al.
CLINICAL INTERVENTIONS IN AGING (2008)
Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
C. Cooper et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A systematic review of persistence and compliance with bisphosphonates for osteoporosis
J. A. Cramer et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density
Kenneth Saag et al.
BONE (2007)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study
A. Cooper et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment
R. Bartl et al.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT (2006)
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)
R Emkey et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Health-related quality of life and radiographic vertebral fracture
W Cockerill et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures
MC Nevitt et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
分享论文
